Recent vaccination announcements have led to some confusion. Four physicians weigh in on who should get vaccinated and when ...

Robert Malone, who believes the U.S. government has “reality-bending information-control capabilities,” will guide the future ...

President Trump’s administration has slammed the brakes on development of messenger RNA (mRNA) vaccines, which proved their ...

CureVac shares skyrocketed 35% Thursday when the biotech firm agreed to be bought by COVID-19 vaccine maker BioNTech in an all-stock deal valued at about $1.25 billion.

(HealthDay News) — The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...

The Gaithersburg, Md., biotechnology company said Wednesday that results of the initial cohort of vaccines showed both the Covid-19-influenza combination and flu-vaccine candidates induced immune ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump administration vs. mRNA vaccines ...

HHS Secretary Robert F. Kennedy Jr. appointed eight new members to the Advisory Committee for Immunization Practices after ...

Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental ...

A large prospective cohort study in Germany found no statistically significant increase in major birth defects following ...

The abrupt termination of the 17 panelists guiding the CDC’s vaccine recommendations could yield a new committee more aligned ...